Blog Immunotherapy 360:

Image

The Immunotherapy 360 blog space features articles that encompass prominent issues related to immunotherapy. These are written with the assistance of the staff at AIM at Melanoma, AIM with Immunotherapy and health care practitioners.

If you have an idea for a future article, please reach out to us on our contact page!

Featured image for “Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable”

Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable

April 23, 2025
Introduction In recent years, several antibody-drug conjugates have received approval for the treatment of gynecological cancers, adding powerful tools to…
Featured image for “Colitis – A Common but Serious Adverse Event”

Colitis – A Common but Serious Adverse Event

December 10, 2024
Immune-related adverse events (irAEs) are unintended consequences of immunotherapies used in cancer treatment. Side effects can range from mild to…
Featured image for “Limits of Success Shown for the Combination of Ipilimumab with Nivolumab”

Limits of Success Shown for the Combination of Ipilimumab with Nivolumab

December 10, 2024
Immunotherapy is a resounding success for the treatment of many cancer types, including those malignancies which previously had no reliable…
Featured image for “Genetics Define Biomarkers of Response to Immunotherapy”

Genetics Define Biomarkers of Response to Immunotherapy

December 10, 2024
Immune checkpoint inhibitor (ICI) therapy, such as nivolumab, pembrolizumab, atezolizumab or combinations with ipilimumab, can be extremely impactful for treating…

Recent Posts

Featured image for “Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable”
Apr. 23, 2025

Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable

Featured image for “Potential Biomarker May Indicate T-VEC Efficacy”
Mar. 18, 2025

Potential Biomarker May Indicate T-VEC Efficacy

Featured image for “Colitis – A Common but Serious Adverse Event”
Dec. 10, 2024

Colitis – A Common but Serious Adverse Event

Post Categories